Research feed
Understand the finding first, then explore the evidence. Choose your reading level and sources independently.
Advanced research filters
Dates show original publication, separately from when we added the story. Clinical trials lists registry activity separately. Check collection coverage.
- Trial registry · no verified findings· University of Padova
Effects of Metformin on Longevity Gene Expression and Inflammation and Prediabetic Individuals. A Placebo-controlled Trial
Trial registry update: COMPLETED. No results reported in the supplied registry record.
Evidence assessment pending
Read the source · University of Padova ↗ - Trial registry · no verified findings· Santen Inc.
A Phase 2, Randomized, Masked, Controlled Clinical Study to Assess the Safety and Efficacy of Lucentis® Plus Sirolimus Versus Lucentis® Plus Placebo in Patients With Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Trial registry update: TERMINATED. No results reported in the supplied registry record.
Evidence assessment pending
Read the source · Santen Inc. ↗ - Trial registry · no verified findings· Santen Inc.
A Phase 1/2, Randomized Clinical Study to Assess the Safety and Efficacy of Sirolimus in Patients With Newly Diagnosed, Treatment-Naive Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Trial registry update: TERMINATED. No results reported in the supplied registry record.
Evidence assessment pending
Read the source · Santen Inc. ↗ - Trial registry · no verified findings· Novartis Pharmaceuticals
RCT of oral everolimus alone or with lucentis for neovascular age-related macular degeneration; results not reported
A randomised, double-masked, parallel group study designed to assess the safety and efficacy of oral everolimus (an mTOR inhibitor in the rapamycin class) alone or combined with lucentis in patients with neovascular age-related macular degeneration. No efficacy or safety results were reported in the material provided.
Evidence assessment pending
Read the source · Novartis Pharmaceuticals ↗